Clofarabine and nelarabine: Two new purine nucleoside analogs

Current Opinion in Oncology

Volumn 18, Issue 6, 2006, Pages 584-590

  Gandhi, Varsha ^a,b   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Center for Experimental Therapeutics   (United States)

Author keywords

Acute leukemias; Arabinosylguanine; Clofarabine; Nelarabine; Purine nucleoside analogs

Indexed keywords

CLOFARABINE; CYCLOPHOSPHAMIDE; DEOXYGUANOSINE TRIPHOSPHATE; DRUG METABOLITE; EVOLTRA; NELARABINE; PURINE NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW SUPPRESSION; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DRUG APPROVAL; DRUG CLEARANCE; DRUG DESIGN; DRUG DNA BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; LEUKEMIA RELAPSE; LIVER TOXICITY; LYMPHOBLASTOMA; NEUROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; T CELL LEUKEMIA; TREATMENT RESPONSE;

ADENINE NUCLEOTIDES; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; HUMANS; LEUKEMIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 33748885763     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000245326.65152.af     Document Type: Review

References (68)

1. Pui CH, Jeha S, Kilpatrick P. Clofarabine. Nat Rev Drug Discovery 2005; 4:369-370. This is a succinct review of clofarabine at the time of its accelerated approval by the FDA.
2. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, et al. Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-β-D- arabinofuranosyladenine. J Med Chem 1992; 35:397-401.
3. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2- fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-trisphosphate. Cancer Res 1991; 51:2386-2394.
4. Carson DA, Wasson DB, Esparza LM, et al. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabino-fluoro- 2′deoxyadenosine. Proc Natl Acad Sci U S A 1992; 89:2970-2974.
5. Parker WB, Allan PW, Hassan AE, et al. Antitumor activity of 2-fluoro-2′-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase. Cancer Gene Ther 2003; 10:23-29.
6. Lotfi K, Mansson E, Spasokoukotskaja T, et al. Biochemical pharmacology and resistance to 2-chloro-2′-arabinofluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clin Cancer Res 1999; 5:2438-2444.
7. Parker WB, Shaddix SC, Rose LM, et al. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-β-D-ribofuranosyl)adenine, 2-chloro-9-(2-deoxy-2,2-difluoro-β-D-ribofuranosyl) adenine in CEM cells. Mol Pharmacol 1999; 55:515-520.
8. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-β-D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res 1995; 55:2847-2852.
9. Gandhi V, Plunkett W, Bonate PL, et al. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia (CLL): strategy for treatment. Clin Cancer Res 2006; 12:4011-4017.
10. Xie KC, Plunkett W. Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-β-D- arabinofuranosyl) adenine. Cancer Res 1996; 56:3030-3037.
11. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. In: Giaccone G, Schilsky R, Sondel P, editors. Cancer chemotherapy and biological response modifiers, Annual 19. Amsterdam: Elsevier Science BV; 2001. pp. 21-45.
12. Chang CH, Cheng YC. Effects of deoxyadenosine triphosphate and 9-beta-D-arabinofuranosyl-adenine 5′-triphosphate on human ribonucleotide reductase from Molt-4F cells and the concept of 'self-potentiation'. Cancer Res 1980; 40:3555-3558.
13. Jiang X, Wang X. Cytochrome C-mediated apoptosis. Annu Rev Biochem 2004; 73:87-106.
14. Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc Natl Acad Sci U S A 1998; 95:9567-9571.
15. Genini D, Budihardjo I, Plunkett W, et al. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 2000; 275:29-34.
16. Genini D, Adachi S, Chao Q, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96:3537-3543.
17. Waud WR, Schmid SM, Harrison SD Jr, et al. Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine, (Cl-F-ara-A). Nucleosides Nucleotides Nucleic Acids 2000; 19:447-460.
18. Takahashi T, Shimizu M, Akinaga S. Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF-CEM. Cancer Chemother Pharmacol 2002; 50:193-201.
19. Kantarjian H, Gandhi V, Kozuch P, et al. Phase I clinical and pharmacology study of clofarabine (chloro-20-fluoro-deoxy-9-beta-D- arabinofuranosyladenine) in patients with solid and hematologic cancers. J Clin Oncol 2003;21:1167-1173.
20. Chiao N, Bumgardner A, Duvic M. Clofarabine-induced acral erythema during the treatment of patients with myelodysplasia and acute leukemia: report of two cases. Leuk Lymphoma 2003; 44:1405-1407.
21. Kantarjian H, Gandhi V, Cortes J, et al. Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemias. Blood 2003; 102:2379-2386.
22. Cooper T, Ayres M, Nowak B, et al. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 2005; 55:361-368.
23. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105:940-947.
24. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108:45-51.
25. Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004; 103:784-789.
26. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukaemia. J Clin Oncol 2006; 24:1917-1923. Full phase II investigation in previously treated pediatric patients with ALL. These data were presented to the FDA for approval of the drug.
27. Jeha S, Razzouk B, Gaynon P, et al. Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias. Proc Am Soc Clin Oncol 2004; 22:800S-8504.
28. Bonate PL, Craig A, Gaynon P, et al. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol 2004; 44:1309-1322.
29. Gandhi V, Kantarjian H, Faderl S, et al. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clinical Cancer Res 2003; 9:6335-6342.
30. Yamauchi T, Nowak B, Keating MJ, et al. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001; 7:3580-3589.
31. Gandhi V, Keating MJ, Bate G, et al. Nelarabine. Nat Rev Drug Discov 2006; 5:17-18. This is a succinct review of nelarabine at the time of its accelerated approval by the FDA.
32. Giblett ER, Ammann AJ, Wara DW, et al. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1975; 1:1010-1013.
33. Cohen A, Gudas LJ, Ammann AJ, et al. Deoxyguanosine triphosphate as a possible toxic metabolite in the immunodeficiency associated with purine nucleoside phosphorylase deficiency. J Clin Invest 1978; 61:1405-1409.
34. Mitchell BS, Mejias E, Daddona PE, et al. Purinogenic immunosufficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Nat Acad Sci U S A 1978; 75:5011-5014.
35. Gelfand EW, Lee JW, Dosch HM. Selective toxicity of purine deoxynucleosides for human lymphocyte growth and function. Proc Nat Acad Sci U S A 1979; 76:1998-2002.
36. Cohen A, Lee J, Dosche HM, et al. The expression of deoxyguanosine toxicity in T lymphocytes at different stages of maturation. J Immunol 1980; 125:1578-1582.
37. Gudas LJ, Ullman B, Cohen A, et al. Deoxyguanosine toxicity in mouse T-lymphoma: relationship to purine nucleoside phosphorylase-associated immune dysfunction. Cell 1978; 14:531-538.
38. Reist EJ, Goodman L. Synthesis of 9-β-D-arabinofuranosylguanine. Biochemistry 1964; 3:15-18.
39. Elion GB, Rideout JL, DeMiranda P, et al. Biological activities of some purine arabinosides. Ann N Y Acad Sci 1975; 255:468-480.
40. Krenitsky TA, Koszalka GW, Tuttle JV, et al. An enzymatic synthesis of purine-D-arabinonucleosides. Carbohydr Res 1981; 97:139-146.
41. Lambe CU, Averett DR, Paff MT, et al. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res 1995; 55:3352-3356.
42. Kisor DF, Plunkett W, Kurtzberg J, et al. The pharmacokinetics of nelarabine and 9-β-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 2000; 18:995-1003.
43. Prus KL, Averett DR, Zimmerman TP. Transport and metabolism of 9-β-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: notrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res 1990; 50:1817-1821.
44. Lewis RA, Link L. Phosphorylation of arabinosyl guanine by a mitochondrial enzyme of bovine liver. Biochem Pharmacol 1989; 38:2001-2006.
45. Wang L, Karlsson A, Arnér ESJ, et al. Substrate specificity of mitochondrial 2′-deoxyguanosine kinase: efficient phosphorylation of 2-chlorodeoxyadenosine. J Biol Chem 1993; 268:22847-22852.
46. Krenitsky TA, Tuttle JV, Koszalka GW, et al. Deoxycytidine kinase from calf thymus: substrate and inhibitor specificity. J Biol Chem 1976; 251:4055-4061.
47. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc Natl Acad Sci U S A 1977; 74:5677-5681.
48. Rodriguez CO Jr, Mitchell BS, Eriksson S, et al. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res 2002; 62:3100-3105.
49. Cohen A, Lee JWW, Gelfand EW. Selective toxicity of deoxyguanosine and arabinosyl guanine for T-leukemic cells. Blood 1983; 61:660-666.
50. Ullman B, Martin DW. Specific cytotoxicity of arabinosyl-guanine toward cultured T-lymphoblasts. J Clin Invest 1984; 74:951-955.
51. Shewach DS, Daddona PE, Ashcraft E, et al. Metabolism and selective cytotoxicity of 9-β-arabinofuranosylguanine in human lymphoblasts. Cancer Res 1985; 45:1008-1014.
52. Verhoef V, Fridland A. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts. Cancer Res 1985; 45:3646-3650.
53. Shewach DS, Mitchell BS. Differential metabolism of 9-β-D- arabinofuranosylguanine in human leukemic cells. Cancer Res 1989; 49:6498-6502.
54. Rodriguez CO Jr, Legha JK, Estey E, et al. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin Cancer Res 1997; 3:2107-2113.
55. Rodriguez CO Jr, Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res 1999; 59:4937-4943.
56. Ono K, Ohashi A, Yamamoto A, et al. Inhibitory effects of 9-β-D-arabinofuranosylguanine 5́-triphosphate and 9-β-D-arabinofuranosyladenine 5′-triphosphate on DNA polymerases from murine cells and oncornavirus. Cancer Res 1979; 39:4673-4680.
57. Gandhi V, Mineishi S, Huang P, et al. Cytotoxicity, metabolism, and mechanisms of action of 2′,2′-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res 1995; 55:1517-1524.
58. Gandhi V, Mineishi S, Huang P, et al. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol 1995; 22:61-67.
59. Rodriguez CO, Stellrecht C, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003; 102:1842-1848.
60. Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005; 23:3396-3403. This is the first phase I investigation of nelarabine in pediatric and adult leukemias and lymphomas. Dose-dependent and lineage-dependent responses are compared in both subgroups of patients.
61. DeAngelo DJ, Yu D, Dodge RK, et al. A phase II study of 9-δ-D-arabinosyl-6methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801. Blood 2002; 100:198a.
62. Thompson MA, Pro B, Sarris A, et al. Results of a phase II study of 506U78 (Nelarabine) in refractory indolent B-cell or peripheral T-cell lymphoma. Blood 2005; 106:753a.
63. Goy A, Bleyer A, Hagemeister F. Phase II study of compound GW506U78 (araG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treated with chemotherapy. Blood 2003; 102:639a.
64. O'Brien S, Thomas D, Kantarjian H, et al. Compound 506 has activity in mature lymphoid leukemia. Blood 1998; 92:490-491a.
65. Berg SL, Blaney SM, DevidasM, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol 2005; 23:3376-3382. Full phase II investigation in previously treated pediatric T-cell leukemias. The schedule was daily for 5 days. These data were presented to the FDA for approval of the drug.
66. Gandhi V, Plunkett W, Rodriguez CO Jr, et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 1998; 16:3607-3615.
67. Gandhi V, Plunkett W, Weller S, et al. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol 2001; 19:2142-2152.
68. Gandhi V, Plunkett W. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol 1989; 38:3551-3558.